Log In
Print
BCIQ
Print
Print this Print this
 

Bexsero

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionMulti-component meningococcal serogroup B vaccine
Molecular Target
Mechanism of ActionVaccine
Therapeutic ModalityPreventive vaccine
Latest Stage of DevelopmentMarketed
Standard IndicationMeningitis
Indication DetailsVaccinate against meningococcal disease
Regulatory Designation

U.S. - Breakthrough Therapy (Vaccinate against meningococcal disease);
EU - Standard Review (Vaccinate against meningococcal disease);
Australia - Standard Review (Vaccinate against meningococcal disease)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today